Top Markets
#1 ADO Protocol ADO Protocol +328.50%
#2 GoPlus Security GoPlus Security +54.02%
#3 Starpower Starpower +38.38%
#4 Verus Coin Verus Coin +33.62%
#5 Tutorial Tutorial +32.38%
#6 Nockchain Nockchain +32.34%
#7 Chainflip Chainflip +28.46%
#8 The Black Bull The Black Bull +26.41%
#9 GAIB AID GAIB AID +24.67%
#10 peaq peaq +17.79%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
NuCana plc NuCana plc

NuCana plc

NCNA
Classifica tra le azioni #32773
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Prezzo delle azioni
$1.51
Capitalizzazione di mercato
$9.14M
Variazione (1 giorno)
-5.35%
Variazione (1 anno)
-59.65%
Paese
GB
Scambia NuCana plc (NCNA)

Categoria

Healthcare
Storico del rendimento da dividendi per NuCana plc (NCNA)
Il rendimento da dividendi (TTM) di NuCana plc (simbolo azionario: NCNA) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per NuCana plc (NCNA) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
0.48%
BE